Fuentes Susana, van Nood Els, Tims Sebastian, Heikamp-de Jong Ineke, ter Braak Cajo J F, Keller Josbert J, Zoetendal Erwin G, de Vos Willem M
Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands.
Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
ISME J. 2014 Aug;8(8):1621-33. doi: 10.1038/ismej.2014.13. Epub 2014 Feb 27.
Recurrent Clostridium difficile infection (CDI) can be effectively treated by infusion of a healthy donor faeces suspension. However, it is unclear what factors determine treatment efficacy. By using a phylogenetic microarray platform, we assessed composition, diversity and dynamics of faecal microbiota before, after and during follow-up of the transplantation from a healthy donor to different patients, to elucidate the mechanism of action of faecal infusion. Global composition and network analysis of the microbiota was performed in faecal samples from nine patients with recurrent CDI. Analyses were performed before and after duodenal donor faeces infusion, and during a follow-up of 10 weeks. The microbiota data were compared with that of the healthy donors. All patients successfully recovered. Their intestinal microbiota changed from a low-diversity diseased state, dominated by Proteobacteria and Bacilli, to a more diverse ecosystem resembling that of healthy donors, dominated by Bacteroidetes and Clostridium groups, including butyrate-producing bacteria. We identified specific multi-species networks and signature microbial groups that were either depleted or restored as a result of the treatment. The changes persisted over time. Comprehensive and deep analyses of the microbiota of patients before and after treatment exposed a therapeutic reset from a diseased state towards a healthy profile. The identification of microbial groups that constitute a niche for C. difficile overgrowth, as well as those driving the reinstallation of a healthy intestinal microbiota, could contribute to the development of biomarkers predicting recurrence and treatment outcome, identifying an optimal microbiota composition that could lead to targeted treatment strategies.
复发性艰难梭菌感染(CDI)可通过输注健康供体粪便悬液有效治疗。然而,尚不清楚哪些因素决定治疗效果。通过使用系统发育微阵列平台,我们评估了从健康供体移植到不同患者前后及随访期间粪便微生物群的组成、多样性和动态变化,以阐明粪便输注的作用机制。对9例复发性CDI患者的粪便样本进行了微生物群的整体组成和网络分析。在十二指肠输注供体粪便前后以及10周的随访期间进行了分析。将微生物群数据与健康供体的数据进行了比较。所有患者均成功康复。他们的肠道微生物群从以变形菌门和芽孢杆菌为主的低多样性疾病状态转变为更具多样性的生态系统,类似于健康供体的生态系统,以拟杆菌门和梭菌属为主,包括产丁酸细菌。我们确定了因治疗而减少或恢复的特定多物种网络和标志性微生物群。这些变化随时间持续存在。对患者治疗前后微生物群的全面深入分析揭示了从疾病状态到健康状态的治疗性重置。确定构成艰难梭菌过度生长生态位的微生物群以及那些推动健康肠道微生物群重新建立的微生物群,可能有助于开发预测复发和治疗结果的生物标志物,确定可导致靶向治疗策略的最佳微生物群组成。